FIGS, Inc. (FIGS), the direct-to-consumer healthcare apparel company best known for its scrubwear and lifestyle products for medical professionals, has staged one of the more dramatic turnarounds in specialty retail. After a multi-year slump that carried shares from a 2021 peak near $50 to a low of $3.56 in April 2025, the stock has re-rated sharply on accelerating revenue growth and a return to meaningful profitability. The question now facing investors is whether the rally still has room to run toward a $20 price target.
FIGS is covered by roughly nine to eleven research firms, and recent revisions have been broadly constructive. Reviewing eight individual targets that can be attributed to specific analysts and firms, the range runs from a low of $15 to a high of $22, producing an overall mean of approximately $18.63. Because that figure is only a few percent above the current price — below the 10% threshold used here — the central target of $20 is calculated as the average of only those targets that exceed the current share price.
On the constructive side, BTIG (Buy, $22), Oppenheimer (Outperform, $22), KeyBanc (Overweight, $20), and Barclays (Overweight, $20) all lifted targets following the company's August earnings report, citing broad-based growth, active customer gains, and international momentum. Roth MKM maintains a Buy with an $18 target. More cautious views persist: Morgan Stanley (Equal-Weight, $15), Goldman Sachs (Neutral, $16), and Telsey Advisory (Market Perform, $16) hold targets below or near the current price, arguing that much of the improvement is already reflected in the valuation. The collective rating is a "Moderate Buy," with six buy ratings and five holds.
The stock traded around $17.74 in mid-October 2026, just under its 52-week high of roughly $17.98 and up more than 150% over the trailing year. Reaching $20 would require a gain of about 13%, a modest move relative to the stock's recent volatility and its history. The path would most plausibly depend on continued execution: sustained double-digit revenue growth, margin expansion, and analysts raising targets further as the company delivers against its raised outlook.
FIGS beat expectations in its most recent quarter, posting earnings per share (EPS) of $0.15 against a $0.07 consensus and revenue of roughly $196.6 million, up 28.8% year over year. For full-year 2026, management guided to 14% to 16% net revenue growth and an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin of 13.0% to 13.2%. Delivering at or above the top end of that range would likely be the clearest fundamental catalyst for the stock to trade toward the higher end of the analyst range.
Several verified drivers underpin the bullish case. The company's active customer base surpassed three million for the first time in early 2026, growing 12.2% year over year, while net revenue per active customer also rose. International revenue has been a standout, growing roughly 50% in the first quarter of 2026, and the company continues to invest in its TEAMS business-to-business platform and physical "Community Hubs."
Gross margins remain structurally strong — around 68% on a trailing basis — reflecting the premium, digital-first model. A debt-light balance sheet and improving return on equity (about 12.5%) give management flexibility. The turnaround in profitability, from EPS of roughly $0.02 in 2024 to an estimated $0.32–$0.37 for 2026, has been a key driver of the re-rating. Continued upward analyst revisions, which have been frequent since late 2025, could keep sentiment supportive.
The principal obstacle is valuation. At around $17.74, the stock trades at a trailing price-to-earnings (P/E) ratio above 50, a multiple that leaves little room for error. If revenue growth decelerates toward the company's longer-term trend — annual growth was under 2% as recently as 2024 — the stock could de-rate even as fundamentals remain solid.
Tariffs and higher freight costs have been recurring headwinds, and management has acknowledged a shift toward reduced discounting that could pressure customer acquisition. Competition in healthcare apparel, along with any softening in consumer spending on discretionary purchases, presents additional risk. The persistence of hold ratings from several large firms — some of which previously carried Sell ratings before lifting targets — signals genuine disagreement about how much of the recovery is already priced in.
Technically, the stock is in a strong uptrend but has entered a meaningful resistance zone. The prior 52-week high near $17.48, set earlier in 2026, was cleared in the most recent surge, leaving the all-time post-IPO context well above at levels near $50. Round-number levels at $18 and $20 may act as psychological resistance, while the $15.78–$16 area — a former buy point and consolidation zone — represents nearby support. Below that, the 50-day moving average near $13.87 and the 200-day average near $13 provide a deeper cushion. The recent breakout on heavy volume suggests momentum, but extended rallies of this magnitude are historically prone to consolidation.
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary, and the targets cited here were set between March and September 2026. Investors should watch the next quarterly earnings release and guidance, any additional target revisions following results, and commentary on international growth, TEAMS adoption, and tariff or freight cost trends. Changes to the adjusted EBITDA margin outlook and active-customer metrics will be especially relevant to whether the stock can sustain a premium multiple.
For traders seeking a systematic view of evolving conditions, Tickeron's AI Daily Buy/Sell Signals offers an artificial intelligence-driven tool that continuously monitors thousands of stocks and ETFs. It generates Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis, helping traders discover opportunities, monitor positions, and identify shifting trends more efficiently. Combined with fundamental research, these signals can help investors stay alert to momentum changes in names like FIGS as they approach key price levels.
The $20 target is a demanding but not extreme benchmark: it represents the average of the analyst targets that currently sit above the market price, rather than a universal consensus. With shares near $17.74, reaching it would require about a 13% advance, which is achievable if FIGS sustains its recent growth and profitability momentum. Strong demand, international expansion, and a resurgent customer base support the case, while a rich valuation and the skepticism of several hold-rated firms represent the main counterweights. The wide $15-to-$22 spread among analysts underscores genuine uncertainty about how much of the recovery is already reflected in the stock. Investors should monitor earnings, guidance, and margin trends before drawing conclusions about whether the rally has further to go.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, FIGS has been loosely correlated with CAL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if FIGS jumps, then CAL could also see price increases.
| Ticker / NAME | Correlation To FIGS | 1D Price Change % | ||
|---|---|---|---|---|
| FIGS | 100% | +0.60% | ||
| CAL - FIGS | 36% Loosely correlated | -1.78% | ||
| WWW - FIGS | 36% Loosely correlated | -0.20% | ||
| SHOO - FIGS | 35% Loosely correlated | -0.83% | ||
| UAA - FIGS | 33% Poorly correlated | -4.30% | ||
| CROX - FIGS | 31% Poorly correlated | -2.37% | ||
More | ||||